These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9924700)

  • 1. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine.
    Sandmaier BM; Oparin DV; Holmberg LA; Reddish MA; MacLean GD; Longenecker BM
    J Immunother; 1999 Jan; 22(1):54-66. PubMed ID: 9924700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).
    Holmberg LA; Oparin DV; Gooley T; Sandmaier BM
    Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S144-51. PubMed ID: 12620152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
    MacLean GD; Reddish MA; Koganty RR; Longenecker BM
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine.
    Holmberg LA; Oparin DV; Gooley T; Lilleby K; Bensinger W; Reddish MA; MacLean GD; Longenecker BM; Sandmaier BM
    Bone Marrow Transplant; 2000 Jun; 25(12):1233-41. PubMed ID: 10871727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer.
    Miles D; Papazisis K
    Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S134-8. PubMed ID: 12620150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of the STn-KLH vaccine (Theratope).
    Ibrahim NK; Murray JL
    Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S139-43. PubMed ID: 12620151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide.
    MacLean GD; Miles DW; Rubens RD; Reddish MA; Longenecker BM
    J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):309-16. PubMed ID: 8877724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theratope vaccine (STn-KLH).
    Holmberg LA; Sandmaier BM
    Expert Opin Biol Ther; 2001 Sep; 1(5):881-91. PubMed ID: 11728222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer vaccine THERATOPE- Biomira.
    Adis International Ltd
    Drugs R D; 2003; 4(4):236-40. PubMed ID: 12848588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis.
    Longenecker BM; Reddish M; Koganty R; MacLean GD
    Adv Exp Med Biol; 1994; 353():105-24. PubMed ID: 7527178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with Theratope (STn-KLH) as treatment for breast cancer.
    Holmberg LA; Sandmaier BM
    Expert Rev Vaccines; 2004 Dec; 3(6):655-63. PubMed ID: 15606349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy.
    Reddish MA; MacLean GD; Poppema S; Berg A; Longenecker BM
    Cancer Immunol Immunother; 1996 Jun; 42(5):303-9. PubMed ID: 8706053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
    Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
    Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.
    Miles DW; Towlson KE; Graham R; Reddish M; Longenecker BM; Taylor-Papadimitriou J; Rubens RD
    Br J Cancer; 1996 Oct; 74(8):1292-6. PubMed ID: 8883420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant.
    Longenecker BM; Reddish M; Koganty R; MacLean GD
    Ann N Y Acad Sci; 1993 Aug; 690():276-91. PubMed ID: 7690215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
    Ragupathi G; Howard L; Cappello S; Koganty RR; Qiu D; Longenecker BM; Reddish MA; Lloyd KO; Livingston PO
    Cancer Immunol Immunother; 1999 Apr; 48(1):1-8. PubMed ID: 10235483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant.
    MacLean GD; Reddish M; Koganty RR; Wong T; Gandhi S; Smolenski M; Samuel J; Nabholtz JM; Longenecker BM
    Cancer Immunol Immunother; 1993; 36(4):215-22. PubMed ID: 8439984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.
    Miles D; Roché H; Martin M; Perren TJ; Cameron DA; Glaspy J; Dodwell D; Parker J; Mayordomo J; Tres A; Murray JL; Ibrahim NK;
    Oncologist; 2011; 16(8):1092-100. PubMed ID: 21572124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen.
    MacLean GD; Bowen-Yacyshyn MB; Samuel J; Meikle A; Stuart G; Nation J; Poppema S; Jerry M; Koganty R; Wong T
    J Immunother (1991); 1992 May; 11(4):292-305. PubMed ID: 1599915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
    Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
    J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.